Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes
- 1 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 11 (8) , e002210
Abstract
Background In heart failure (HF) with reduced ejection fraction, 2 clinical trials, the BEST (β-Blocker Evaluation of Survival Trial) and HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), have reported an effectiveness interaction between the ADRB1 (β-1 adrenergic receptor) Arg389Gly polymorphism and β-blockers (BBs). HF-ACTION additionally reported a dose-related interaction of unclear origin. If confirmed and pharmacogenetically resolved, these findings may have important implications for HF with reduced ejection fraction precision therapy. We used uniform methodology to investigate BB dose-ADRB1 Arg389Gly polymorphism interaction with major clinical end points in BEST/bucindolol and HF-ACTION/other BB databases. Methods This was a retrospective analysis of prospectively designed DNA substudies from BEST (N=1040) and HF-ACTION (N=957). Subjects were genotyped for ADRB1 Arg389Gly and ADRA2C (α2C adrenergic receptor) Ins322-325Del. BB dose was defined as either no/...Keywords
This publication has 20 references indexed in Scilit:
- Potential Applications of Pharmacogenomics to Heart Failure TherapiesHeart Failure Clinics, 2014
- Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor PolymorphismJACC: Heart Failure, 2013
- Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart FailureJAMA, 2013
- Association between Adrenergic Receptor Genotypes and Beta-Blocker Dose in Heart Failure Patients: Analysis from the HF-ACTION DNA SubstudyEuropean Journal of Heart Failure, 2013
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart FailureCardiovascular Drugs and Therapy, 2010
- Polymorphisms of Adrenoceptors are Not Associated With an Increased Risk of Adverse Event in Heart Failure: A MERIT-HF SubstudyJournal of Cardiac Failure, 2009
- Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated With Carvedilol or MetoprololJACC, 2008
- A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failureProceedings of the National Academy of Sciences, 2006
- β-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure*Clinical Pharmacology & Therapeutics, 2005